London, United Kingdom, September 01, 2018 --(PR.com
)-- There’s just under 4 weeks until SMi’s Immuno-Oncology Conference commences in London on the 26th and 27th September.
The event aims to propagate thought-provoking discussions about the future of Immuno-Oncology between industry leaders, and update delegates on current key areas for development, advancements in therapy and revisions of regulations.
The study of immuno-oncology has been ever-present in recent news, with biomarkers in melanoma having been recently identified by Dana-Farber Cancer Institute and Women's Cancer Center that could potentially help tailor immunotherapy treatments to patients in order to maximize the benefits, whilst decreasing the chance of severe side effects.
In recent years, advanced melanoma patients' future prospects has greatly improved due to immune checkpoint inhibitors, drugs which stimulate the body's immune system to attack cancer.* Immune checkpoint inhibitors have greatly contributed to improved cancer survival rates, with studies, advancements and developments in the field being one of the main focuses of this year's Immuno-Oncology Conference.
The two-day event is set to provide delegates with an overview of the latest developments in the field of immuno-therapy, with key updates on:
· CAR T-Cell Therapy
· Cancer vaccines
· Bi-specific antibodies
· Combination therapies
· Clinical collaborations
· Applications of liquid biopsies, and much more.
This year's conference will also host two pre-conference interactive workshops on 25th September, which will aim to expand attendees' understanding of current, relevant topics in the industry:
Workshop A: “Strategic Competitive Intelligence in the Immuno-Oncology space” led by Timos Papagatsias, CEO, LucidQuest Ventures, will focus on how stakeholders can combine the latest advancements in Strategic Competitive Intelligence in order to uncover opportunities and threats for their companies and brands in the Immuno-Oncology space.
Workshop B: “Could the Microbiome boost cancer immunotherapy?” led by Shahram Lavasani, CEO, ImmuneBiotech, and Ramin Massoumi, Principal Investigator, Lund University, will cover recent advances in the understanding of the complex role of the microbiome in health and disease, and how microbes and the microbiota may contribute to cancer development, as well as responsiveness to cancer therapeutics.
Visit the website to download the latest brochure, view the full speaker-line up and other exclusive content. Register your place for the conference and accompanying workshops at:
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk